Motley Fool Health-Care Analyst David Williamson discusses the earnings report and conference call released yesterday from Sarepta, and talks about why it may be the next biotech company to keep your eye on. Like any biotech company in the development stage, Sarepta didn't have a whole lot of earnings to report, but the conference call was full of great information. Williamson breaks down all the things he liked, and some of the things he didn't, from this exciting company's quarter.
David Williamson owns no shares of the companies mentioned. Follow him on Twitter @MotleyDavid. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Here's What Pushed Arena Pharmaceuticals, Inc. Up 10.6% in November
A robust clinical-stage pipeline helped investors forget about Arena's ill-fated weight-loss drug.
The Single Event That Rocketed Arena Pharmaceuticals, Inc. Higher by 10% in October
You could say that Arena "posterized" Wall Street in October and was rewarded for it.
Here's What Lifted Arena Pharmaceuticals, Inc. Stock in September
Preclinical data strengthened the case for Arena's lead candidate.